Sylvia Kang

She came to the United States with two suitcases, broken English, and what she later called "a stubborn belief." That belief wasn't vague. It was specific: that the tools women used to understand their own bodies were embarrassingly inadequate, and that someone with the right training could do something about it.

Mira started on her kitchen table. Today it occupies Times Square. The distance between those two points is measured not in dollars - though Mira has raised $8.8M and generates $6M in annual revenue - but in the 50,000 women who have conceived naturally using a device Sylvia invented, tested, and used herself.

The Long Way Around

She grew up in China, where she began piano training at age four. By her early teens she was winning international piano competitions in France, China, and Hong Kong. The conservatory track felt like a settled life - until it wasn't.

At 18, still enrolled in music school, she began a parallel education from her grandfather's library. Physics books, read in secret. Six years of self-study alongside formal musical training, leading her eventually to biomedical engineering. Her grandfather had encouraged this pivot - an unconventional path for a young woman in China at the time.

She eventually earned an MS in Biomedical Engineering from Columbia University and an MBA from Cornell's Johnson Graduate School of Management. Then came a stint at Corning Incorporated, the Fortune 500 life science company, where she managed a $100M global business operation. The move from concert hall to corner office to kitchen-table startup was not a straight line - it was the kind of route that only makes sense in retrospect.

What She Saw That Others Missed

She watched a close friend struggle with fertility. Then another. Then she started paying attention to the data: roughly 80% of people experience some form of hormone imbalance, and up to 30% of couples receive an "unexplained infertility" diagnosis - which often means "we don't actually know what's happening."

In 2016, she co-founded what was then called Quanovate (later rebranded as Mira). The product she built - the Mira Hormone Monitor - tracks multiple reproductive hormones including LH, estrogen, FSH, and PdG using fluorescent sensor technology, delivering quantitative readings rather than binary yes/no results. The device achieved 99% accuracy in clinical trials.

She integrated AI into the platform in 2018, well before "AI-powered" became a marketing cliche in health tech. The timing was deliberate: she wanted the algorithm learning on real user data early, so that by the time the mainstream caught up, Mira would have a dataset none of its competitors could replicate quickly.

The Personal Proof Point

Mira is the first FDA and CE-registered comprehensive at-home women's hormone monitoring platform. But the credential that appears most often in interviews with Sylvia isn't the regulatory stamp - it's the fact that she used her own product to conceive after age 35.

That specific detail carries a particular weight in a category where founder credibility matters enormously. She wasn't evangelizing a technology she'd built for others. She was her own user, her own test case, her own evidence.

"We deserve to make confident decisions with personalized and accurate results," she has said. "Just like I did, when I used Mira to conceive after 35."

The company has since helped over 50,000 women conceive naturally. That number keeps growing.

Running the Machine

The work of scaling from kitchen table to 140-person company is not romantic. Sylvia has been candid about the isolation that comes with it: "I wasn't prepared for how isolating running a business would become within my own personal circles." As her frame of reference shifted toward long-term impact and leadership development, conversations with friends who were tracking different milestones became harder to sustain.

Her solution was practical: she built overlapping support circles rather than relying on any single relationship - hiking companions, mindfulness groups, fellow founders who understood the specific texture of startup life. The approach reflects the same instinct she brings to the product: segment the need, build systems for it, keep them running in parallel.

She identifies three traits she considers essential to running Mira: persistence, open-mindedness, and team-building. She is also specific about what open-mindedness actually requires - welcoming criticism, because "critical feedback is essential to business growth," and starting every product decision from the user's perspective rather than from what the technology can do.

Beyond Fertility

Mira is no longer just an ovulation tracker. Sylvia's stated ambition is to build the world's largest continuous hormone dataset - one that connects cycle-specific hormone patterns to health outcomes across a woman's entire life. The platform now covers PCOS management, menopause transition, fertility coaching, prenatal vitamins, and virtual consultations.

Her 2024 Built In essay - "How Can Employers Help Women in Menopause Thrive as Leaders?" - and the July 2025 Fitt Insider podcast episode both point in the same direction: she is building the case that hormone data, properly collected and interpreted, changes not just individual health decisions but workplace policy and public health research.

The Ultra4 device - Mira's most advanced technology, launched in 2024 with a Times Square campaign - represents the hardware side of this ambition. The software side is the AI model, trained on data from 200,000+ users, refining its predictions with every cycle logged.

Recognition That Doesn't Come Easy

She navigates a cultural tension she describes directly: traditional Chinese values that reward quiet excellence sit uncomfortably alongside the entrepreneurial world's demand for self-promotion and visibility. Her advice to other women: "If we don't ask, we won't get the opportunity." She has learned to practice what she preaches.

In 2024, Inc. Magazine named her to the Female Founders 250 - a list culled from thousands of entries across quantifiable metrics: revenue, growth, funding, audience size. Femtech World named her Leader of the Year. Fast Company listed Mira among the World's Most Innovative Companies. Healthline named Mira's device the Best Fertility Monitor of 2024.

None of those recognitions existed when she was reading her grandfather's physics books at midnight in a music school dormitory. But the stubbornness that drove that late-night reading is exactly what built the company that earned them.